Cantor Fitzgerald Predicts InflaRx FY2025 Earnings

InflaRx (NASDAQ:IFRX) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for InflaRx in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings per share of ($0.87) for the year. Cantor Fitzgerald has a “Overweight” rating and a $10.00 price target on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share.

IFRX has been the topic of several other reports. Guggenheim raised their target price on InflaRx from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a research report on Friday, March 21st.

InflaRx Price Performance

NASDAQ:IFRX opened at $1.85 on Thursday. The business’s 50-day moving average is $1.20 and its two-hundred day moving average is $1.82. The firm has a market capitalization of $124.20 million, a PE ratio of -1.71 and a beta of 2.21. InflaRx has a 12 month low of $0.82 and a 12 month high of $2.82.

InflaRx (NASDAQ:IFRX) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.

Institutional Trading of InflaRx

Large investors have recently modified their holdings of the business. Northern Trust Corp lifted its stake in shares of InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock worth $1,647,000 after acquiring an additional 634,045 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of InflaRx in the 4th quarter valued at approximately $1,576,000. Commonwealth Equity Services LLC boosted its stake in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after buying an additional 19,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after buying an additional 11,900 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of InflaRx during the fourth quarter worth approximately $55,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.